ArticleDiabetologia2013
Matrix metalloproteinase-10 plays an active role in microvascular complications in type 1 diabetic patients.
Article in Diabetologia, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 45 citations in OpenAlex.
- Macroalbuminuria as a marker of cardiac damage in patients with type 2 diabetes: insights from multimodality cardiac imaging and biomarkers.Journal of physiology and biochemistry · 2026Article
- Liquid Biopsy Combined with Multi-Omics Approaches in Diagnosis, Management, and Progression of Diabetic Retinopathy.Biomedicines · 2025Review
- Matrix metalloproteinase-10 promotes kidney fibrosis by transactivating β-catenin signaling.Cell death discovery · 2025Article
- Notch3 deletion regulates HIV-1 gene expression and systemic inflammation to ameliorate chronic kidney disease.Disease models & mechanisms · 2025Article
- Assessment of causality between circulating inflammatory proteins and subtypes of diabetic retinopathy.International journal of ophthalmology · 2025Article
- Notch3 deletion regulates HIV-1 gene expression and systemic inflammation to ameliorate chronic kidney disease.bioRxiv : the preprint server for biology · 2024Article
- Comprehensive analysis of molecular mechanisms underlying kidney stones: gene expression profiles and potential diagnostic markers.Frontiers in genetics · 2024Article
- An insight into novel therapeutic potentials of taxifolin.Frontiers in pharmacology · 2023Review
- Association between Circulating Levels of 25-Hydroxyvitamin DNutrients · 2022Article
- Up-Date on Diabetic Nephropathy.Life (Basel, Switzerland) · 2022Review
- Matrix Metalloproteinase 10 Contributes to Choroidal Neovascularisation.Biomedicines · 2022Article
- Matrix Metalloproteinase-10 in Kidney Injury Repair and Disease.International journal of molecular sciences · 2022Review
- Taxifolin improves inflammatory injury of human bronchial epithelial cells by inhibiting matrix metalloproteinase (MMP) 10 via Wnt/β-catenin pathway.Bioengineered · 2022Article
- Matrix metalloproteinase-10 protects against acute kidney injury by augmenting epidermal growth factor receptor signaling.Cell death & disease · 2021Article
- Matrix Metalloproteinases in Age-Related Macular Degeneration (AMD).International journal of molecular sciences · 2020Review
- Circulating TIMP-1 is associated with hematoma volume in patients with spontaneous intracranial hemorrhage.Scientific reports · 2020Article
- Prolyl Hydroxylase Domain Inhibitor Protects against Metabolic Disorders and Associated Kidney Disease in Obese Type 2 Diabetic Mice.Journal of the American Society of Nephrology : JASN · 2020Article
- Matrix Metalloproteinases in Diabetic Kidney Disease.Journal of clinical medicine · 2020Review
- Growth differentiation factor 15 (GDF-15) is a potential biomarker of both diabetic kidney disease and future cardiovascular events in cohorts of individuals with type 2 diabetes: a proteomics approach.Upsala journal of medical sciences · 2020Article
- MMP-10 is Increased in Early Stage Diabetic Kidney Disease and can be Reduced by Renin-Angiotensin System Blockade.Scientific reports · 2020Observational
Corrections and comments
- Commented on by
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
aims/hypothesisThe role of metalloproteinase-10 (MMP-10) in type 1 diabetes is not known. We hypothesise that it plays a role in the onset and progression of diabetic nephropathy and retinopathy.
methodsSerum MMP-10 levels from 269 patients with type 1 diabetes were measured, and their association with microvascular complications was analysed. We also studied whether knocking out the Mmp10 gene influenced the extent of renal injury and retinal damage in a streptozotocin-induced diabetic mouse model.
resultsThe risk of nephropathy and proliferative retinopathy associated with the highest vs the lowest MMP-10 tertile was increased three to four times independently of the classical risk factors. Accordingly, renal function and morphology were better preserved in diabetic Mmp10 −⁄− mice than in their Mmp10 +/+ counterparts. There were more kidney-infiltrating macrophages in diabetic Mmp10+/+ mice, suggesting that MMP-10 contributes to the inflammatory response leading to microvascular complications. The loss of neuronal cells in the retinas of diabetic Mmp10 +/+ mice was higher than in Mmp10 −⁄− mice. Retinal inflammation was decreased in Mmp10 −⁄− mice, as indicated by their reduced retinal caspase-1 levels. CONCLUSIONS/
interpretationMMP-10 is involved in the development of microvascular complications in type 1 diabetes and emerges as a potential therapeutic target for slowing down the evolution of diabetic nephropathy and retinopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.